Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research
Activity Outline
FDA Grand Rounds: Stable Isotope Ratio Analysis – An Important Tool in the Fight Against Food Fraud
April 11, 2024
virtual

Activity Coordinators:
Isaac Miller (Isaac.Miller@fda.hhs.gov),  Rokhsareh Shahidzadeh (Rokhsareh.Shahidzadeh@fda.hhs.gov)
Series Description

The FDA Grand Rounds highlights cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.

Lecture Description
Adding substances to high quality/price commodities for economic gain is a growing problem that can be difficult to spot. One tool the FDA uses is stable isotope ratio analysis (SIRA), which has proved to be invaluable in detection of this adulteration. This presentation will explain the basics of SIRA, including relevant instrumentation, and applications to various FDA regulated products.
References
  • Madhavi Mantha, John R Urban, William A Mark, Anatoly Chernyshev, Kevin M Kubachka, “Direct Comparison of Cavity Ring Down Spectrometry and Isotope Ratio Mass Spectrometry for Detection of Sugar Adulteration in Honey Samples,” Journal of AOAC INTERNATIONAL, 101 (6), 1857-1863, 2018, https://doi.org/10.5740/jaoacint.17-0491
  • Kristen M. Hannon, Joshua D. Sabala, Madhavi Mantha, Lisa M. Lorenz, John P. Roetting II, Matteo Perini, Silvia Pianezze, Kevin M. Kubachka, “Using stable carbon isotope ratio analysis to detect adulteration in red yeast rice dietary supplements,” Talanta, 266 (2), 125076, (2024), https://doi.org/10.1016/j.talanta.2023.125076
  • Madhavi Mantha, Kevin M Kubachka, John R Urban, Catherine O Dasenbrock, Anatoly Chernyshev, William A Mark, Christine France, Michelle Chartrand, Jonathan Hache, Sylvain Decoeur, Haiping Qi, “Economically Motivated Adulteration of Lemon Juice: Cavity Ring Down Spectroscopy in Comparison with Isotope Ratio Mass Spectrometry: Round-Robin Study,” Journal of AOAC INTERNATIONAL, 102 (5), 1544–1551, https://doi.org/10.1093/jaoac/102.5.1544
Series Objectives
  • Discuss the research conducted at the FDA
  • Explain how FDA science impacts public health
Learning Objectives After completion of this activity, the participant will be able to:
  • Describe economic adulteration and how isotope ratio analysis is an important tool.
  • Explain how instrumentation used for isotopic ratio analysis operates.
  • Discuss applications for this analysis and share findings from completed work.
Target Audience
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.
Registration Information
Registration is complimentary; therefore refunds are not applicable. For information on how to register to attend this activity, please contact the Activity Coordinator(s) listed above.
Agenda

Lecture 1 April 11, 2024
Time Topic Speaker
12:00 - 1:00 PM EDT Stable Isotope Ratio Analysis – An Important Tool in the Fight Against Food Fraud Kevin Kubachka, PhD
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-24-017-L99-P for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit

All learners claiming credit must attest to their attendance and complete all required activity evaluation(s) in the FDA CE Portal (ceportal.fda.gov) within 14 days after an activity ends. Upon completion, learners may view/print statement of credit.

Attention NABP Pharmacists and Pharmacy Technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy (NABP) provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor®. If you do not see your credit reflected on CPE Monitor®* after 45 days of attestation, please contact FDACETeam@fda.hhs.gov.
*CPE Monitor® sets a strict 60-day limit on uploading credits.

Disclosure

Faculty
  • Kubachka, Kevin, PhD, Chemist, US FDA - Forensic Chemistry Center - nothing to disclose

Planning Committee
  • Dinatale, Miriam, DO, Team Leader, Food and Drug Administration - nothing to disclose
  • Pfundt, Tiffany, PharmD, Program Coordinator, FDA/CDER/OTBB - nothing to disclose
  • Shahidzadeh, Rokhsareh, RN, MSN, Senior Regulatory Health Education Specialist, FDA - nothing to disclose

CE Consultation and Accreditation Team
  • Faberlle, Alexandra M., Training Specialist / FDA/CDER/OEP/DLOD - nothing to disclose
  • Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated.
All relevant financial relationships have been mitigated.